Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Leukemic stem cell signatures identify novel therapeutics targeting acute myeloid leukemia

6 Jun 2018

Abstract excerpt

Therapy for acute myeloid leukemia (AML) involves intense cytotoxic treatment and yet approximately 70% of AML are refractory to initial therapy or eventually relapse. This is at least partially driven by the chemo-resistant nature of the leukemic stem cells (LSCs) that sustain the disease, and therefore novel anti-LSC therapies could decrease relapses and improve survival. We performed in silico analysis of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Myeloid Leukemia Research
Share to Histone Deacetylase Inhibitors Research
Share to Protein Degradation and Inhibitors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 29921955
DOI: 10.1038/s41408-018-0087-2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Leukemic stem cell signatures identify novel therapeutics targeting acute myeloid leukemiaPMID 29921955Read ↗

Discovery of agents that eradicate leukemia stem cells using an in silico screen of public gene expression dataSemantic proximity Read ↗

Therapeutic targeting of acute myeloid leukemia stem cellsSemantic proximity Read ↗

Update on Small Molecule Targeted Therapies for Acute Myeloid Leukemia.Semantic proximity Read ↗

Patient-tailored design of AML cell subpopulation-selective drug combinationsSemantic proximity Read ↗

Dasatinib response in acute myeloid leukemia is correlated with FLT3/ITD, PTPN11 mutations and a unique gene expression signature.Semantic proximity Read ↗

Large-Scale In Vitro and In Vivo CRISPR-Cas9 Knockout Screens Identify a 16-Gene Fitness Score for Improved Risk Assessment in Acute Myeloid LeukemiaSemantic proximity Read ↗

Enhanced sensitivity to glucocorticoids in cytarabine-resistant AMLSemantic proximity Read ↗

Leukotrienes promote stem cell self-renewal and chemoresistance in acute myeloid leukemiaSemantic proximity Read ↗

Upregulation of Genetic Markers of Poor Prognosis following Chemotherapy in Acute Myeloid Leukemia CellsSemantic proximity Read ↗

Identification of AML1-ETO modulators by chemical genomicsSemantic proximity Read ↗

Induction of leukemic stem cell differentiation by aryl hydrocarbon receptor agonist and synergy with gilteritinib in FLT3-ITD + acute myeloid leukemia.Semantic proximity Read ↗

Heterogeneity in refractory acute myeloid leukemiaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.